Target intelligence / Profile preview

Paternally-expressed gene 3 protein (PEG3)

Target
PEG3
Molecular classification
Transcription factor, Zinc finger protein, Krüppel-type (C2H2) zinc finger protein, Imprinted gene product
01

Overview

Paternally-expressed gene 3 protein (PEG3) is a large, multifunctional, paternally imprinted transcription factor encoded by the PEG3 gene, which is expressed exclusively from the paternal allele[3][1][6]. It is characterized by twelve C2H2-type Krüppel zinc finger domains and an N-terminal SCAN domain that facilitates homo- and heterodimerization, essential for its combinatorial regulation of target genes[1][7]. PEG3 regulates gene expression by binding DNA in a sequence-specific manner and primarily functions as a transcriptional repressor for its downstream genes, including other imprinted loci[5][1]. PEG3 participates in diverse biological processes such as fetal growth control, maternal and nurturing behavior, autophagy, apoptosis via p53, repression of Wnt/β-catenin signaling, regulation of mitochondrial genes, and metabolic reprogramming[2][5][4]. It is a critical tumor suppressor frequently dysregulated in cancer through epigenetic silencing (hypermethylation), and its loss is implicated in multiple human malignancies[2][4][6]. PEG3 is also recognized as a marker of competent self-renewing adult stem cells, and its proper regulation is required for cell differentiation and developmental processes[4]. PEG3 can interact with proteins such as SIAH1, TRAF2, and β-catenin, modulating key signaling pathways in cell survival, death, and metabolism[1][3]. Despite its importance in development and disease, PEG3 is not currently considered a direct pharmaceutical target, and no drugs are known to act on PEG3 directly. Its epigenetic status and loss of expression provide potentially valuable biomarkers for cancer prognosis and patient selection[2][6]. No specific safety concerns exist tied to direct targeting, though dysregulation of PEG3 or therapies impacting imprinting could have pleiotropic developmental and oncogenic risks.

Other names
Paternally-expressed gene 3 proteinPEG3KIAA0287ZSCAN24ZKSCAN22ZNF904Zinc finger and SCAN domain-containing protein 24PW1Kruppel-type zinc finger protein
02

Biological functions

Transcriptional regulationTumor suppressionApoptosisAutophagy regulationDevelopmental programmingRegulator of cell proliferationMitochondrial and metabolic regulationCell differentiationRegulation of pluripotencyModulation of cell adhesion and migrationRepression of downstream genesFetal growth controlMaternal and nurturing behaviorRepression of Wnt/β-catenin signaling
03

Disease associations

Cancer (including glioma, ovarian cancer, cervical carcinoma, breast cancer, clear cell renal carcinoma)Neurodevelopmental and behavioral syndromes (related to imprinting and fetal growth)Mesenchymal hamartoma of the liverPulmonary arterial hypertension
04

Safety considerations

PEG3 is not a direct therapeutic target; no drugs currently target PEG3, but mechanisms involving its loss or dysregulation might raise safety issues for therapies affecting imprinting, epigenetic regulation, or broad transcriptional repressionDysregulation of PEG3 or therapies impacting imprinting could have pleiotropic developmental and oncogenic risks
05

Biomarkers

Loss or reduction of PEG3 expression (tumor suppressor biomarker in several cancers)Aberrant methylation/hypermethylation of PEG3 promoter (cancer epigenetic biomarker)Marker for self-renewing adult stem cells

Beyond the preview

Go deeper on Paternally-expressed gene 3 protein (PEG3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paternally-expressed gene 3 protein (PEG3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call